In hepatoma, HepaRG cells and human hepatocytes, the SLCO1B1, SLCO2B1, SLC22A1 and SLC22A7 expression was down-regulated by an RAR agonist, all-trans retinoic acid [221]. Here, SLC22A1 is linked to hepatocellular carcinoma.